ClinConnect ClinConnect Logo
Search / Trial NCT06998095

Tezepelumab (Tezspire) Regulatory Postmarketing Surveillance in Korea

Launched by ASTRAZENECA · May 29, 2025

Trial Information

Current as of July 23, 2025

Not yet recruiting

Keywords

Severe Asthma

ClinConnect Summary

This clinical trial is studying a medication called tezepelumab (also known as Tezspire) for people with severe asthma in South Korea. The main goals of the study are to see how well this medication works and to understand any side effects that patients might experience while using it. The trial is not yet recruiting participants, but when it starts, it will include adults aged 18 and older who have received at least one dose of tezepelumab as prescribed by their doctor.

To be considered for this study, patients must have given their consent to participate, meaning they understand what the trial involves. However, those who are using tezepelumab for reasons not approved by health authorities or are currently involved in another clinical trial will not be eligible. Participants can expect to be monitored for their asthma symptoms and any side effects while taking the medication, helping researchers gather important information about its use in real-world settings.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • 1. Patients who are treated with at least one dose of tezepelumab according to the indication in the locally approved prescribing information
  • 2. Patients with evidence of a personally signed and dated informed consent document indicating that the patient (or a legally acceptable representative) has been informed of all pertinent aspects of the study
  • Exclusion Criteria:
  • 1. Other off-label indications according to the locally approved prescribing information
  • 2. Current participation in any interventional trial

About Astrazeneca

AstraZeneca is a global biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative medicines across various therapeutic areas, including oncology, cardiovascular, respiratory, and autoimmune diseases. With a strong commitment to scientific research and patient-centric solutions, AstraZeneca leverages cutting-edge technology and a robust pipeline to address unmet medical needs. The company collaborates with healthcare professionals, academic institutions, and other organizations to advance clinical trials and deliver transformative therapies, aiming to improve health outcomes and enhance the quality of life for patients worldwide.

Locations

Patients applied

0 patients applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported